Tag: Thryv Therapeutics

Thryv therapeutics inc thryv therapeutics announces 30 million

Thryv Therapeutics Announces $30 Million Financing to Launch the ASPIRE-HF Study in Patients with Heart Failure; Wave II Efficacy Cohort Fully Enrolled in Long QT Syndrome

Financial by 0 comments

$30 million Series B financing led by InClin, Inc., a global contract research organization, with continued support from existing investors ASPIRE-HF, a Phase 2a study of THRV-1268 in heart failure with reduced ejection fraction and QTc prolongation, opens for enrollment in early 2027…

Continue Reading →

Thryv Therapeutics Receives FDA IND Clearance of THRV-1268 for Clinical Programs in Heart Failure and Atrial Fibrillation and Presents Results of SGK1 Inhibition Combined with Jardiance (empagliflozin), an SGLT2 inhibitor, in a Pressure Overload Heart Failure Model at ESC Congress 2025

Rhythm by 0 comments

MONTREAL, Sept. 8, 2025 /PRNewswire/ – Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for cardiovascular diseases, today announced the presentation of preclinical results demonstrating…

Continue Reading →